Form 4: Director Alexis Borisy Receives Relay Therapeutics Options

Director Alexis Borisy was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Alexis Borisy received a grant of 32,947 stock options on June 9, 2026.
• The options have an exercise price of $14.09 per share.
• The options are set to expire on June 8, 2036.
• The grant vests in full on the earlier of the first anniversary of the grant date or the date of the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $14.09 exercise price.

Future Outlook

The options vest in full within one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Relay Therapeutics, RLAY, Form 4, Insider Trading, Stock Options, Director Compensation